Burden of thalassemia in children
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at the medical, financial, and emotional impact of thalassemia on children and their families. It aims to understand the burden of the disease to improve support and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be diagnosed with thalassemia.
- Child must be between 2 and 18 years old.
- Child must have regular follow-up at a pediatric hematology clinic or thalassemia unit.
- Child must not have any other chronic blood disorder unrelated to thalassemia.
- Child must not have a severe acute illness at the time of data collection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how severe thalassemia is in children and teens. If your child has thalassemia and is between 18 months and 18 years old, joining may help doctors better understand the condition.
This study looks at body composition in children with thalassemia major who receive regular blood transfusions. It aims to understand how the condition and treatment affect body fat, muscle, and overall health.
This study looks at what factors might affect growth in children with beta-thalassemia major who get regular blood transfusions. It aims to help understand and manage growth problems better.
This study looks at emotional and mental health challenges in children aged 6 to 12 who have thalassemia. It aims to understand these problems so doctors can offer better support.
This study tests a medicine called luspatercept to see if it safely helps children with beta-thalassemia need fewer blood transfusions or keep their hemoglobin levels stable. It is for children aged 6 to 17 who either get regular transfusions or have low hemoglobin and few transfusions.
This study looks at how children with transfusion-dependent beta-thalassemia grow and develop after gene therapy. It compares children who have had gene therapy with those who have not, and also with healthy children of the same age and gender.
Hear when a new Thalassemia Particularly Transfusion Dependent Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.